Navid Manouchehri
Overview
Explore the profile of Navid Manouchehri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sguigna P, Hussain R, Okai A, Blackburn K, Tardo L, Madinawala M, et al.
Ther Adv Neurol Disord
. 2024 Apr;
17:17562864241233858.
PMID: 38585373
Background: Individual disease modifying therapies approved for multiple sclerosis (MS) have limited effectiveness and potentially serious side effects, especially when administered over long periods. Sequential combination therapy is a plausible...
2.
Saadatnia M, Zandifar A, Alizadeh M, Ub Kim J, Shafaat O, Tierradentro-Garcia L, et al.
Adv Biomed Res
. 2023 Jul;
12:136.
PMID: 37434927
Background: We aimed to investigate the usefulness of intracranial arterial pulsatility index to assess the prognosis of lacunar infarcts. Materials And Methods: Forty-nine patients with confirmed acute lacunar infarct were...
3.
Lambracht-Washington D, Fu M, Manouchehri N, Hynan L, Stuve O, Rosenberg R
Aging Brain
. 2023 Mar;
3:100066.
PMID: 36911262
Background: To investigate how changes in expression of glial genes relate to a progression of Alzheimer's disease (AD) pathology, and how anti-Aβ immunotherapy impact these changes, we conducted a transcriptomic...
4.
Manouchehri N, Salinas V, Hussain R, Stuve O
Proc Natl Acad Sci U S A
. 2023 Feb;
120(6):e2212696120.
PMID: 36730207
In the context of autoimmunity, myeloid cells of the central nervous system (CNS) constitute an ontogenically heterogeneous population that includes yolk sac-derived microglia and infiltrating bone marrow-derived cells (BMC). We...
5.
Ashtari F, Manouchehri N, Shaygannejad V, Barekatain M, Adibi I, Afshari-Safavi A, et al.
Mult Scler Relat Disord
. 2023 Jan;
70:104492.
PMID: 36587484
Background: Cognitive impairment is common in people living with neuromyelitis optica spectrum disease (NMOSD) and multiple sclerosis (MS). However, there is little published data on intelligence quotient (IQ) in NMOSD...
6.
Hussain R, Sguigna P, Okai A, Wright C, Madinawala M, Bass A, et al.
J Cent Nerv Syst Dis
. 2022 Sep;
14:11795735221123911.
PMID: 36062026
Background: Natalizumab is a recombinant humanized monoclonal antibody (mAb) against α4-integrin that is approved for relapsing forms of multiple sclerosis (MS). Natalizumab is associated with an increased risk of developing...
7.
Manouchehri N, Shirani A, Salinas V, Tardo L, Hussain R, Pitt D, et al.
Neurol Neurochir Pol
. 2022 Jun;
56(3):228-235.
PMID: 35712986
For the past four decades, multiple sclerosis (MS) has been a focus for clinical trial development and execution. Advances in translational neuroimmunology have led to the development of effective disease-modifying...
8.
Manouchehri N, Salinas V, Rabi Yeganeh N, Pitt D, Hussain R, Stuve O
Front Neurol
. 2022 Apr;
13:854390.
PMID: 35432156
The advent of disease modifying therapies (DMT) in the past two decades has been the cornerstone of successful clinical management of multiple sclerosis (MS). Despite the great strides made in...
9.
Tugemann B, Manouchehri N, Stuve O
Mult Scler Relat Disord
. 2022 Jan;
59:103541.
PMID: 35078128
No abstract available.
10.
Manouchehri N, Stuve O
Proc Natl Acad Sci U S A
. 2021 Sep;
118(40).
PMID: 34583997
No abstract available.